Education and Career
Jeanmarie Guenot has excellent academic credentials, possessing a postgraduate degree from the Wharton School, University of Pennsylvania. She also holds a doctorate from the San Francisco campus of the University of California. She is the boss at Amphivena Therapeutics, an institution that is committed to eradicating hematological cancers through the development of antibody therapies.
Guenot possesses vast knowledge of the pharmaceutical and life science industries. In her exemplary career spanning two decades, she has served in different capacities in leading firms. Her experience covers venture capital, business development, and pharmaceutical research.
JeanMarie’s first job was at the Atlas Venture. The company dealt with the financing of bio technology-oriented start-ups. Her work entailed the development of early stage biotechnology companies and management of venture capital investments. She joined Hoffman- La Roche., Where she was a business adviser. It was Hoffman that she started working in oncology and autoimmune diseases. Later, she joined PDL BioPharma.
During her time at PDL, she engineered purchases and mergers, as well as recording extraordinary profit margins. One of the noteworthy mergers was between the firm and Biogen Idec., which saw the two companies join forces in the development of products. The merger, worth $800 million, involved stage 2 cancer patients and three autoimmune drug candidates.
In her outstanding career, Jeanmarie Guenot has been acknowledged by receiving many prestigious awards. In 2005, she won Innovative Bio-Partnering Award from the BioBusiness Network. The following year she got the Deal of Distinction Award from the Licensing Executives Society.
Since the exemplary Jeanmarie Guenot took the helm at Amphivena, the company has made significant breakthroughs in the fight against cancers of the blood. The institution’s objective is to mitigate the effects of hematological cancers by restoration of cellular balance in the circulatory system. After restoration, the immune system will be in a position to obstruct the formation of tumors or spreading of the existing ones.
A notable invention was recently approved by the Food and Drug Administration (FDA) for use in phase 1 cancer patients. The new drug is a remedy for acute myeloid leukemia.
Since its inception in 2013, Amphivena Therapeutics has made significant advancements in the fight against blood cancers. The approval of their drug is a testament to this developments. With research still in progress, cancer patients can expect better oncology solutions in the future.